filgotinib king jak increas estim jak deep dive
invest summari reiter overweight increas price
target cantor small-mid-cap analyst elli merl
deep dive jak industri space link conjunct
galapago launch link base deep dive work increas
peak filgotinib sale estim sale variou
indic agre key call deep dive jak inhibitor
promis big class therapi could use beyond ra recal
gilead book revenu us profit split glpg
benelux region filgotinib key pipelin product glpg also
gilead
agre finch data high strateg import
compar profil biggest competitor upadacitinib
cover current filgotinib rheumatoid arthriti estim still
view estim conserv could see upsid data robust
particularli focus vs humira thought
refractori patient look competit upadcitinib discuss acr
abstract releas posit upcom readout ra filgotinib
finch studi clean toler standpoint think
manag team discuss fda faster file
timelin would signific strateg posit upadcitinib ahead
filgotinib get us market could launch late filgotinib
us base case drug file complet male
safeti studi call manta due preclin find test
think gild/glpg could file without manta could advanc file timelin
year base case howev manta studi requir
ex-u region would expect compani file oversea
break adjust filgotinib estim indic ra
spondyl scheme thing estim could potenti
conserv class larg filgotinib turn best class
disclosur section may found page
use probability-adjust dcf analysi valu gilead share assum discount rate
model revenu assum termin valu
risk overweight rate price target includ hiv gener competit risk
particularli gsk cover brand side slower less success biktarvi
launch expect slow car-t sale current competit emerg next-gen
car-t failur cell therapi modal grow drive stabil growth long term
late-stag pipelin failur particularli nash franchis filgotinib trial
clinic regulatori commerci risk prevent franchis contribut
million except ep
hiv hbv
royalti contract revenu
provis incom tax
net incom gilead non-
net incom non-control interest
net loss non-control interest
growth ep dilut
net incom
non- reconcili
acquisit relat amort intang
acquisition-rel amort inventori mark-up
million except ep
acquisit relat amort intang
non- incom
incom tax effect non-gaap adjust
tax non-gaaap adjust
cog total
 total
sg total
issuanc stock share buyback
chang work capit
present valu flow
npv
npv termin valu
tv
million except ep
growth total hcv
growth total hiv
japan broken
japan broken
epclusa japan
japan
million except ep
million except ep
filgotinib ra crohn
unadjust sale gilead
adjust sale gilead
year
po see filgotinib summari break-out
adjust sale gilead
patient number
econom gilead unadjust sale
total net sale gilead
econom gilead adjust sale
total net sale gilead
gilead global biopharmaceut compani major base busi revenu base infecti diseas
pipelin evolv inflamm oncolog nash compani headquart foster citi california
